about
Phase 1 Trials of rVSV Ebola Vaccine in Africa and EuropeA Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary ReportSmallpox DNA vaccine protects nonhuman primates against lethal monkeypoxDepletion of Alveolar Macrophages Does Not Prevent Hantavirus Disease Pathogenesis in Golden Syrian HamstersThe Syrian hamster model of hantavirus pulmonary syndromeAntiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposureSide-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primatesStructural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 proteinA lethal disease model for hantavirus pulmonary syndromeProduction of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal CattleDNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS)A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS).DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys.An attenuated Machupo virus with a disrupted L-segment intergenic region protects guinea pigs against lethal Guanarito virus infection.A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates.Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.Andes virus M genome segment is not sufficient to confer the virulence associated with Andes virus in Syrian hamsters.Treatment of hantavirus pulmonary syndromeHuman T-cell responses to vaccinia virus envelope proteins.Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome.Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamstersPreclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and FilovirusesCodon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challengesImmune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus.Glycoprotein-Specific Antibodies Produced by DNA Vaccination Protect Guinea Pigs from Lethal Argentine and Venezuelan Hemorrhagic Fever.Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome--after intranasal exposure to Andes virusA lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus.The strategic use of novel smallpox vaccines in the post-eradication world.A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation.Efficient production of Hantaan and Puumala pseudovirions for viral tropism and neutralization studies.Study of Andes virus entry and neutralization using a pseudovirion system.Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.DNA vaccines for HFRS: laboratory and clinical studies.A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome.Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters.Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates.
P50
Q24289281-2A87755B-C0A3-4F05-8193-6FCDAA2369F8Q24289295-101EC6C2-F2BB-44D0-8492-F9F0CE7C72E3Q24623839-B6A7483F-CFC2-497C-9AB8-A35038E657F0Q26314485-8C7EE00F-534F-4889-826F-08F9A5E00411Q27027405-D4584011-24EA-4C3D-9824-0ECDCC9109CFQ27304441-4EB05930-5645-4651-8B2E-F01E2ED87A13Q27325586-7DE25FBC-F34E-42C6-B91C-3D85481AEC07Q27647102-94B8957A-6C0A-4992-863D-8C8A2BFF0042Q28198563-52F8800E-5AD8-4E90-8F41-8384D68F4400Q28603849-786E4633-1B1D-432B-B660-2FA39B12587CQ28730275-695F5976-4E40-4E96-86DA-D3E531CDD71BQ33567784-8B68FDAF-DC54-46E6-8B5D-4B5325F80C14Q33854252-42F1B9DE-59F7-4A44-8E98-828E2B6747B5Q33875495-BB42C107-4CC6-4013-BAD5-3C4138DC518EQ34165062-7908DE5B-AEF1-4F58-8CB0-FB06B12BB2CCQ34289866-535DD9B9-AC70-45FB-9C9A-FF19069AD34CQ34334411-35C48309-31E6-41CA-A36D-B52B7B129D09Q34727873-A71801A9-9D9C-43CE-B54A-5DE460BDDA08Q35101531-71633D39-7E17-42C8-A53A-447E7B50E06AQ35339702-AB6D9870-B34E-4EED-8FA6-EB450B15224BQ35383088-0C7EF24D-5004-4C72-A808-389A99766F6DQ35793699-52B234C0-9619-499B-91AC-5ECDCB47381DQ35914518-12C2A5F0-33C3-4447-B808-D3C295AF57BBQ36043269-5F4970B8-521E-483B-BC3D-4B7701AA7DF9Q36255716-F659E724-496E-40E2-A7D5-4031C03B818DQ36424202-0A5D443C-DB04-407B-8CE3-5BB99DB6844EQ36694022-F536087A-2CF2-450D-A77F-E3BB8DB42167Q37376384-A97406D7-B48D-444A-B7BD-760F274DD79DQ37547578-B66F450E-EC13-409A-AE70-5BFC48736AD0Q37909421-BDD8D1F0-6F0E-4783-B7E5-3A0ABCCDD71DQ38442265-910655A5-787C-40B1-87C4-714759F13CD4Q39419672-2A7F0DD1-CC8D-4649-9C20-27DDBFC4E399Q39776670-5FB2822B-0D5E-4DBD-A98D-9B1549B21AE3Q40116397-6B025253-72FD-4E6F-A54A-A4EFEF5F6FEFQ40144208-26465C3A-5275-4D62-AC45-E16A9E589BDFQ40177646-131FAF72-12D9-4A4F-B26C-36832FF3F820Q40223653-BA5F130C-0BA6-47D3-AFC5-7E8340BFCEAAQ40299060-AD55F83F-EB69-4DD9-8E97-0BF4F6B030E4Q40419118-1282EB03-5E25-4821-8FD5-296C2266B4C5Q40490115-14B1F122-5EC9-4C05-9977-5631E3BCCBF0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jay W Hooper
@es
Jay W. Hooper
@en
Jay W. Hooper
@nl
Jay W. Hooper
@sl
type
label
Jay W Hooper
@es
Jay W. Hooper
@en
Jay W. Hooper
@nl
Jay W. Hooper
@sl
altLabel
Jay W Hooper
@en
prefLabel
Jay W Hooper
@es
Jay W. Hooper
@en
Jay W. Hooper
@nl
Jay W. Hooper
@sl
P1053
K-2362-2017
P106
P1153
7102438481
P21
P31
P3829
P496
0000-0002-4475-0415
P569
2000-01-01T00:00:00Z